Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study

Lloret-Linares, Célia; Rollason, Victoria; Ing Lorenzini, Kuntheavy; Samer, Caroline Flora; Daali, Youssef; Gex-Fabry, Marianne; Aubry, Jean-Michel; Desmeules, Jules Alexandre; Besson, Marie

doi:10.1016/j.phrs.2016.07.002

Scientific article

English

Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study

ContributorsLloret-Linares, Célia; Rollason, Victoria; Ing Lorenzini, Kuntheavy

; Samer, Caroline Flora

; Daali, Youssef; Gex-Fabry, Marianne; Aubry, Jean-Michel; Desmeules, Jules Alexandre; Besson, Marie

Published inPharmacological research, vol. 118, p. 104-110

Publication date2017

Abstract

This retrospective study aimed to assess to what extent an adverse drug reaction (ADR), an abnormal therapeutic drug monitoring (TDM) or a non-response, was attributable to an abnormal cytochrome P450 activity in a psychiatric setting.

Affiliation entities

Research groups

Citation (ISO format)

LLORET-LINARES, Célia et al. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. In: Pharmacological research, 2017, vol. 118, p. 104–110. doi: 10.1016/j.phrs.2016.07.002

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:86303
DOI : 10.1016/j.phrs.2016.07.002
PMID : 27378571

Journal ISSN1043-6618

666views

201downloads

Creation23/08/2016 13:24:00

First validation23/08/2016 13:24:00

Update15/03/2023 00:39:28

Status update15/03/2023 00:39:27

Last indexation18/08/2025 11:30:55

Archive ouverte UNIGE

Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study

This retrospective study aimed to assess to what extent an adverse drug reaction (ADR), an abnormal therapeutic drug monitoring (TDM) or a non-response, was attributable to an abnormal cytochrome P450 activity in a psychiatric setting.

Technical informations